Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity

Journal of Investigative Dermatology

Volumn 132, Issue 2, 2012, Pages 410-420

  Cedeno Laurent, Filiberto ^a,b   Opperman, Matthew J ^a   Barthel, Steven R ^a,b   Hays, Danielle ^a   Schatton, Tobias ^a,c   Zhan, Qian ^a   He, Xiaoying ^b,d   Matta, Khushi L ^e   Supko, Jeffrey G ^b,d   Frank, Markus H ^a,c   Murphy, George F ^a,b   Dimitroff, Charles J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUORO GLUCOSAMINE; GALECTIN 1; GAMMA INTERFERON; GLUCOSAMINE; INTERLEUKIN 10; N ACETYLLACTOSAMINE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84855974833     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.335     Document Type: Article

References (44)

1. Allen HJ, Ahmed H, Matta KL (1998) Binding of synthetic sulfated ligands by human splenic galectin 1, a beta-galactoside-binding lectin. Glycoconj J 15:691-5 (Pubitemid 28380332)
2. Andre S, Kojima S, Yamazaki N et al. (1999) Galectins-1 and-3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J Cancer Res Clin Oncol 125:461-74 (Pubitemid 29410410)
3. Banh A, Zhang J, Cao H et al. (2011) Tumor Galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 71:4423-31
4. Barthel SR, Antonopoulos A, Cedeno-Laurent F et al. (2011) Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N-and O-glycans without direct incorporation. J Biol Chem 286:21717-31
5. Barthel SR, Wiese GK, Cho J et al. (2009) Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci USA 106:19491-6
6. Catalina MD, Estess P, Siegelman MH (1999) Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation: participation of E-and P-but not L-selectin. Blood 93: 580-9 (Pubitemid 29035739)
7. Cedeno-Laurent F, Barthel SR, Opperman MJ et al. (2010) Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol 185: 4659-72
8. Clausse N, van den Brule F, Waltregny D etal. (1999) Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3:317-25 (Pubitemid 129643974)
9. Daniels MA, Hogquist KA, Jameson SC (2002) Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol 3:903-10 (Pubitemid 35154002)
10. Descheny L, Gainers ME, Walcheck B etal. (2006) Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetyl- glucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol 126:2065-73
11. Dimitroff CJ, Bernacki RJ, Sackstein R (2003a) Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 101: 602-10 (Pubitemid 36077583)
12. Dimitroff CJ, Kupper TS, Sackstein R (2003b) Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 112:1008-18 (Pubitemid 38056316)
13. Fuzii HT, Travassos LR (2002) Transient resistance to B16F10 melanoma growth and metastasis in CD43-/-mice. Melanoma Res 12:9-16 (Pubitemid 34183684)
14. Gainers ME, Descheny L, Barthel SR et al. (2007) Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J Immunol 179:8509-18
15. Hirata T, Furie BC, Furie B (2002) P-, E-, and L-selectin mediate migration of activated CD8+ T lymphocytes into inflamed skin. J Immunol 169: 4307-13 (Pubitemid 35178203)
16. Ilarregui JM, Croci DO, Bianco GA etal. (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregula-tory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10:981-91
17. Ito K, Scott SA, Cutler S et al. (2011) Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 14:293-307
18. Jung EJ, Moon HG, Cho BI et al. (2007) Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. IntJ Cancer 120:2331-8
19. Juszczynski P, Ouyang J, Monti S et al. (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104:13134-9 (Pubitemid 351737605)
20. Karmakar S, Stowell SR, Cummings RD et al. (2008) Galectin-1 signaling in leukocytes requires expression of complex-type N-glycans. Glyco-biology 18:770-8
21. Kortylewski M, Komyod W, Kauffmann ME et al. (2004) Interferon-gamma- mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 122: 414-22 (Pubitemid 38281063)
22. Motran CC, Molinder KM, Liu SD etal. (2008) Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur J Immunol 38:3015-27
23. Nagahara K, Arikawa T, Oomizu S etal. (2008) Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181:7660-9
24. Ouyang J, Juszczynski P, Rodig SJ et al. (2011) Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117:4315-22
25. Pace KE, Lee C, Stewart PL et al. (1999) Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 163:3801-11 (Pubitemid 29450905)
26. Perillo NL, Pace KE, SeilhamerJJ etal. (1995) Apoptosis of Tcells mediated by galectin-1. Nature 378:736-9
27. Rabinovich GA, Ilarregui JM (2009) Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 230:144-59
28. Rabinovich GA, Liu FT, Hirashima M et al. (2007) An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol 66:143-58 (Pubitemid 47063211)
29. Rubinstein N, Alvarez M, Zwirner NW et al. (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241-51 (Pubitemid 38402116)
30. Sakuishi K, Apetoh L, Sullivan JM et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187-94
31. Sharma M, Bernacki RJ, Paul B et al. (1990) Fluorinated carbohydrates as potential plasma membrane modifiers. Synthesis of 4-and 6-fluoro derivatives of 2-acetamido-2-deoxy-D-hexopyranoses. Carbohydr Res 198:205-21
32. Staite ND, Justen JM, Sly LM et al. (1996) Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin. Blood 88:2973-9 (Pubitemid 26357378)
33. Stannard KA, Collins PM, Ito K et al. (2010) Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. Cancer Lett 299: 95-110
34. Thijssen VL, Barkan B, Shoji H et al. (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70:6216-24
35. Thijssen VL, Hulsmans S, Griffioen AW (2008) The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 172:545-53 (Pubitemid 351282039)
36. Thijssen VL, Postel R, Brandwijk RJ et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-80 (Pubitemid 44657577)
37. Toscano MA, Bianco GA, Ilarregui JM et al. (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8:825-34 (Pubitemid 47099035)
38. van den Brule F, Califice S, Garnier F et al. (2003) Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest 83:377-86 (Pubitemid 36350999)
39. van der Leij J, van den Berg A, Harms G et al. (2007) Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol 44: 506-13 (Pubitemid 44287047)
40. Weishaupt C, Munoz KN, Buzney E et al. (2007) T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 13:2549-56 (Pubitemid 46788020)
41. Wells JW, Cowled CJ, Farzaneh F et al. (2008) Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 181:3422-31
42. Woynarowska B, Dimitroff CJ, Sharma M et al. (1996) Inhibition of human HT-29 colon carcinoma cell adhesion by a 4-fluoro-glucosamine analogue. Glycoconj J 13:663-74 (Pubitemid 26271285)
43. Woynarowska B, Skrincosky DM, Haag A et al. (1994) Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 269:22797-803 (Pubitemid 24273393)
44. Zhou Q, Munger ME, Veenstra RG et al. (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501-10